Indication

Non-cystic fibrosis bronchiectasis

Non-cystic fibrosis bronchiectasis is a chronic, progressive pulmonary disease characterized by permanent, abnormal dilation and destruction of the bronchial walls occurring independently of cystic fibrosis transmembrane conductance regulator gene mutations. Read more about Non-cystic fibrosis bronchiectasis

1 drugs 1 manufacturers

Drugs that treat it

Common Non-cystic fibrosis bronchiectasis therapies.

Showing 1–1 of 1 drugs

Sort

BRINSUPRI (brensocatib)

NON-CYSTIC FIBROSIS BRONCHIECTASIS

INSMED INCORPOR

Filter & compare in the drug finder →Opens the drug finder with Non-cystic fibrosis bronchiectasis preselected.

News & literature

Coming soon

Related codes

Coming soon

About Non-cystic fibrosis bronchiectasis.

Primarily affecting the lower respiratory tract across adult and pediatric populations, it arises from diverse etiologies, including recurrent infections, immunodeficiencies, primary ciliary dyskinesia, and autoimmune conditions, or may remain idiopathic.

Pathophysiologically, impaired mucociliary clearance initiates a vicious cycle of persistent bacterial colonization, neutrophilic airway inflammation, and structural tissue elastolysis.

Patients clinically manifest with chronic productive cough, excessive sputum production, dyspnea, and recurrent infective exacerbations that contribute to progressive airflow obstruction and loss of lung function.

nih.gov
Non-cystic fibrosis bronchiectasis is a chronic, progressive pulmonary disease characterized by permanent, abnormal dilation and destruction of the bronchial walls occurring independently of cystic fibrosis transmembrane conductance regulator gene mutations Patients clinically manifest with chronic productive cough, excessive sputum production, dyspnea, and recurrent infective exacerbations that contribute to progressive airflow obstruction and loss of lung function
nih.gov
Non-cystic fibrosis bronchiectasis is a chronic, progressive pulmonary disease characterized by permanent, abnormal dilation and destruction of the bronchial walls occurring independently of cystic fibrosis transmembrane conductance regulator gene mutations
nih.gov
Primarily affecting the lower respiratory tract across adult and pediatric populations, it arises from diverse etiologies, including recurrent infections, immunodeficiencies, primary ciliary dyskinesia, and autoimmune conditions, or may remain idiopathic
thoracic.org
Primarily affecting the lower respiratory tract across adult and pediatric populations, it arises from diverse etiologies, including recurrent infections, immunodeficiencies, primary ciliary dyskinesia, and autoimmune conditions, or may remain idiopathic
nih.gov
Primarily affecting the lower respiratory tract across adult and pediatric populations, it arises from diverse etiologies, including recurrent infections, immunodeficiencies, primary ciliary dyskinesia, and autoimmune conditions, or may remain idiopathic
nih.gov
Pathophysiologically, impaired mucociliary clearance initiates a vicious cycle of persistent bacterial colonization, neutrophilic airway inflammation, and structural tissue elastolysis Patients clinically manifest with chronic productive cough, excessive sputum production, dyspnea, and recurrent infective exacerbations that contribute to progressive airflow obstruction and loss of lung function
nih.gov
Pathophysiologically, impaired mucociliary clearance initiates a vicious cycle of persistent bacterial colonization, neutrophilic airway inflammation, and structural tissue elastolysis

Personalize your experience

Follow Non-cystic fibrosis bronchiectasis and get updates as they land.

Create a free account

Already a member? Sign in

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it